- Home
- INCY vs ASTS Comparison
INCY vs ASTS Comparison
Compare INCY & ASTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | INCY | ASTS |
|---|---|---|
| Founded | 1991 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Commercial Physical & Biological Resarch | Telecommunications Equipment |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.0B | 19.4B |
| IPO Year | 1993 | N/A |
Fundamental Metrics
Financial Performance| Metric | INCY | ASTS |
|---|---|---|
| Price | $102.46 | $74.03 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 20 | 9 |
| Target Price | ★ $90.71 | $59.37 |
| AVG Volume (30 Days) | 2.0M | ★ 10.6M |
| Earning Date | 10-28-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 3878.02 | N/A |
| EPS | ★ 5.90 | N/A |
| Revenue | ★ $4,813,105,000.00 | $18,531,000.00 |
| Revenue This Year | $19.59 | $1,223.27 |
| Revenue Next Year | $10.88 | $363.99 |
| P/E Ratio | $17.37 | ★ N/A |
| Revenue Growth | 18.09 | ★ 641.24 |
| 52 Week Low | $53.56 | $17.50 |
| 52 Week High | $109.28 | $102.79 |
Technical Indicators
Market Signals| Indicator | INCY | ASTS |
|---|---|---|
| Relative Strength Index (RSI) | 54.83 | 62.62 |
| Support Level | $100.55 | $52.20 |
| Resistance Level | $107.61 | $57.81 |
| Average True Range (ATR) | 2.94 | 5.09 |
| MACD | -0.98 | 2.14 |
| Stochastic Oscillator | 45.19 | 95.81 |
Price Performance
Historical ComparisonAbout INCY Incyte Corp.
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.
About ASTS AST SpaceMobile Inc.
AST SpaceMobile Inc is a satellite designer and manufacturer. The company is building a cellular broadband network in space to operate directly with standard, unmodified mobile devices, and off-the-shelf mobile phones based on extensive IP and patent portfolio. It has focused on eliminating the connectivity gaps faced by mobile subscribers. The Company's spaceMobile Service is being designed to provide cost-effective, high-speed Cellular Broadband services to end-users who are out of terrestrial cellular coverage using existing mobile devices.